Clearance of carbonyl-modified lipoproteins from the bloodstream of rabbits
https://doi.org/10.12737/article_590823a4b59f98.13160142
Abstract
We have suggested that the molecular mechanism of vascular wall damage in diabetes is not substantially different from that in atherosclerosis. Thus, it can be assumed that aldehyde-modified LDL should be eliminated from the blood stream with much greater speed than non-oxidized LDL. In the available literature there is information about the clearance of native human LDL from the bloodstream, whereas information on the clearance of the aldehyde-modified LDL in animals or humans was not found. Based on this, the present work is devoted to the clearance of aldehyde-modified LDL of rabbits and humans introduced into the bloodstream of rabbits. We investigated the clearance of glyoxal-, methylglyoxal- and MDA-modified LDL from the bloodstream of rabbits. We used biotinylated LDL of rabbit blood plasma and FITC-labeled LDL of human blood plasma. LDL was isolated with preparative ultracentrifugation in NaBr gradient. It was shown that glyoxal- and methylglyoxal-modified LDL of rabbits and humans circulated in the bloodstream for the same time as native LDL while MDA-modified LDL was rapidly eliminated from the bloodstream. The data obtained indicated the possibility of greater atherogenic potential of glyoxal- and methylglyoxal-modified LDL as they circulate in the bloodstream for a rather long time. At the same time, MDA-modified LDL is likely to be exposed to enhanced elimination by macrophages after their "linkage" to blood cells.
About the Authors
M. A. Grechnikova
Russian Cardiology Research and Production Complex
Russian Federation
Russian Federation
S. P. Domogatskiy
Russian Cardiology Research and Production Complex
Russian Federation
Russian Federation
G. G. Konovalova
Russian Cardiology Research and Production Complex
Russian Federation
Russian Federation
A. K. Tikhaze
Russian Cardiology Research and Production Complex
Russian Federation
Russian Federation
V. Z. Lankin
Russian Cardiology Research and Production Complex
Russian Federation
Russian Federation
References
1. Ланкин В.З., Тихазе А.К., Капелько В.И., Шепелькова Г.С., Шумаев К.Б., Панасенко О.М., Коновалова Г.Г., Беленков Ю.Н. Механизмы окислительной модификации липопротеидов низкой плотности при окислительном и карбонильном стрессе // Биохимия. - 2007. - Т. 72, № 10. - С. 1330-1341
2. Bayer EA, Wilchek M (1990). Protein biotinylation. Meth. Enzymol., (184), 138-160.
3. Cartun RW, Pedersen CA (1989). An immunocytochemical technique offering increased sensitivity and lowered cost with a streptavidin-horseradish peroxidase conjugate. J. Histotechnol., 12 (4), 273-277.
4. Goldstein JL, Brown MS (2009). History of discovery: the LDL receptor. Arterioscler. Thromb. Vasc. Biol., 29 (4), 431-438.
5. Gylling H, Kontula K, Miettinen TA (1995). Cholesterol absorption and metabolism and LDL kinetics in healthy men with different apoprotein E phenotypes and apoprotein B Xba I and LDL receptor Pvu II genotypes. Arterioscler. Thromb. Vasc. Biol., (15), 208-213.
6. Jomova K, Valko M (2011). Advances in metal-induced oxidative stress and human disease. Toxicology, 283 (2-3), 65-87.
7. Lankin VZ, Tikhaze AK (2003). Free radical lipoperoxidation during atherosclerosis and antioxidative therapy of this disease. Free Radicals, Nitric Oxide, and Inflammation: Molecular, Biochemical, and Clinical Aspects (Tomasi A (eds.) et al.). NATO Science Series, (344), 218-231.
8. Lankin VZ, Konovalova GG, Tikhaze AK, Shumaev KB, Kumskova EM, Viigmaa M (2014). The initiation of free radical peroxidation of low-density lipoproteins by glucose and its metabolite methylglyoxal: a common molecular mechanism of vascular wall injure in atherosclerosis and diabetes. Mol. Cell. Biochem., 395 (1-2), 241-252.
9. Lankin VZ, Tikhaze AK, Konovalova GG, Kumskova EM, Shumaev KB (2010). Aldehyde-dependent modification of low-density lipoproteins. Handbook of lipoprotein research (Rathbound JE (ed.)), 85-107.
10. Lankin VZ, Tikhaze AK, Kumskova EM (2012). Macrophages actively accumulate malonyldialdehyde-modified but not enzymatically oxidized low-density lipoprotein. Mol. Cell. Biochem., 365 (1-2), 93-98.
11. Lindgren FT (1975). Preparative ultracentrifugal laboratory procedures and suggestions for lipoprotein analysis. Analysis of lipids and lipoproteins (Perkins EG (ed.)). Amer. Oil. Chemists’Soc., 204-224.
12. Miettinen TA, Gylling H, Vanhanen H, Ollus A (1992). Cholesterol absorption, elimination, and synthesis related to LDL kinetics during varying fat intake in men with different apoprotein E phenotypes. Arteriosclerosis Arterioscler. Thromb. Vasc. Biol., (12), 1044-1052.
13. Niedowicz DM, Daleke DL (2005). The role of oxidative stress in diabetic complications. Cell. Biochem. Biophys., 43 (2), 289-330.
14. Requena JR, Fu MX, Ahmed MU, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR (1997). Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoprotein. Biochem. J., 322, 317-325.
15. Staines WA, Meister B, Melander T, Nagy JI, Hokfelt TJ (1988). Three-color immunofluorescence h istochemistry allowing triple labeling within a single section. Histochem. Cytochem, (36), 145-151.
16. Tertov VV, Kaplun VV, Dvoryantsev SN, Orechov AN (1995). Apolipoprotein B-bound lipids as a marker for evaluation of low-density lipoprotein oxidation in vivo. Biochem. Biophys. Res. Commun., (214), 608-613.
17. Witz G (1989). Biological interactions of α,β-unsaturated aldehydes. Free Rad. Biol. Med., (7), 333-349.
18. Yla-Herttuala S (1991). Macrophages and oxidized low-density lipoproteins in the pathogenesis of atherosclerosis. Ann. Med., 23 (5), 561-567.
Review
For citations:
Grechnikova M.A., Domogatskiy S.P., Konovalova G.G., Tikhaze A.K., Lankin V.Z. Clearance of carbonyl-modified lipoproteins from the bloodstream of rabbits. Acta Biomedica Scientifica. 2016;1(3(2)):104-108. (In Russ.) https://doi.org/10.12737/article_590823a4b59f98.13160142
Views:
752
.png)
Email this article 
